CSF3R and myeloproliferative neoplasm, unclassifiable: Grouped analysis revealed that patients with MDS/MPN-U and CMML demonstrated the highest CSF3R VAFs (median, 39%; range, 26–49%), consistent with a predominant clonal driver role.